Clinical Trials Logo

Filter by:
  • Not yet recruiting  
  • Page [1]
NCT ID: NCT06249815 Not yet recruiting - Induction of Labor Clinical Trials

Sequential Use of Foley's Catheter and Misoprostol Versus Misoprostol Alone for Induction of Labour: a Multicentre Randomised Controlled Trial

Start date: April 26, 2024
Phase: Phase 4
Study type: Interventional

Evaluation of efficacy of inducing labour using a Foley's catheter and low dose oral misoprostol sequentially, in comparison with low dose oral misoprostol alone.

NCT ID: NCT06068140 Not yet recruiting - Clinical trials for Chronic Viral Hepatitis B With Delta-Agent

Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort Study

Start date: December 2023
Phase:
Study type: Observational

The goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis D in real clinical practice: a prospective cohort study

NCT ID: NCT05645419 Not yet recruiting - Clinical Study Clinical Trials

Chronoprognosis of Myocardial Infarction in Patients With Type 2 Diabetes Mellitus

Start date: February 2023
Phase: N/A
Study type: Interventional

Purpose: To develop a mathematical model for the occurrence of MI in patients with T2D by studying the relationship between the internal personalized biorhythms of the patients and the external transit rhythms of space objects; to develop and implement a personalized method of chrono-prevention of MI in patients with T2D. Obejectives: 1.1 To investigate patterns of the influence of external transit rhythms of space objects on the occurrence of MI in patients with T2D: an observational study using clinical databases. 1.2 To investigate patterns of influence of cyclic activity of helio- and geophysical phenomena in the interplanetary medium on the occurrence of MI in patients with T2D. 2. Develop a mathematical model for predicting the occurrence of MI in patients with T2D, based on the identification of the relationship patterns between the internal personalized biorhythms of these patients and the external transit rhythms of space objects. 3. To investigate the effectiveness of the mathematical model for predicting the occurrence of MI in patients with T2D for the purpose of personalized chrono-prevention: a randomized clinical trial.

NCT ID: NCT05484505 Not yet recruiting - Smoking Cessation Clinical Trials

Preloaded Combination Nicotine Replacement Therapy on Smoking Cessation of Adult Population in Kazakhstan

Start date: July 1, 2023
Phase: Early Phase 1
Study type: Interventional

Randomized, controlled, two-armed, single-blinded, superiority trial with 1:1 allocation ratio Nicotine Replacement Therapy(NRT)

NCT ID: NCT05060705 Not yet recruiting - Covid19 Clinical Trials

"Efesovir" (FS-1) for COVID-19, Phase 2

Start date: December 2025
Phase: Phase 2
Study type: Interventional

Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".

NCT ID: NCT04702685 Not yet recruiting - Pain, Postoperative Clinical Trials

Erector Spinae Plane Block With Ropivacaine for Major Upper Abdominal Surgery

Start date: January 2021
Phase: Phase 3
Study type: Interventional

Prospective, single-centre, randomized, controlled, open-label, evaluator-blinded, superiority trial.

NCT ID: NCT03222167 Not yet recruiting - Metabolic Syndrome Clinical Trials

Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

Start date: October 2017
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-label trial of Elbasvir/ Grazoprevir 50/100 mg fixed dose combination 12 week treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with of metabolic syndrome. The study to be conducted in conformance with Good Clinical Practices. A total of 60 subjects will be studied at 2 sites in the Republic of Kazakhstan. Males and Females treatment naïve patients with CHC genotype 1b infection associated with metabolic syndrome (MS), 18-70 years of age, with or without severe fibrosis / compensated cirrhosis will be enrolled. SVR 12 (primary endpoint) will be evaluated. Patients will be stratified by fibrosis stage and presence of metabolic syndrome components. Interim Analysis will be performed in order to estimate viral kinetics, applicability of SVR4 and durability of SVR12 by evaluation of virologic response at week 4 and 8 of treatment and follow-up at week 4 (SVR 4) and 24 will be performed - this will be a descriptive summary only without hypothesis testing. The main hypothesis is that 12-week therapy with MK-5172 in combination with MK-8742 for treatment-naïve patients with HCV genotype 1b with metabolic syndrome is not notably worse than the same course for treatment-naïve patients with HCV genotype 1b without metabolic syndrome.